FAM156A: A Potential Drug Target and Biomarker for Familial Adenylate Calbindinoma

Target Name: FAM156A

NCBI ID: G29057

FAM156A

FAM156A: A Potential Drug Target and Biomarker for Familial Adenylate Calbindinoma

Introduction

Familial adenylate calbindinoma (FAC) is a rare autosomal recessive disorder caused by mutations in the FAM156A gene, which encodes a protein involved in the intracellular signaling pathway known as the calcium-dependent protein kinase (Ca2+-dependent protein kinase) or Calmodulin- dependent protein kinase (CaM-PK). This gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Although several studies have identified potential drug targets and biomarkers for FAC, the full extent of its role in these processes remains unclear.

FAM156A Gene and its Function

The FAM156A gene is a member of the Calbindin gene family, which is known for its involvement in the regulation of intracellular signaling pathways, including the Ca2+-dependent protein kinase (Ca2+-dependent protein kinase) and CaM-PK. The Ca2+- Ca2+-dependent protein kinase is a protein that plays a crucial role in the regulation of calcium homeostasis, while CaM-PK is a protein that modulates the activity of Ca2+-dependent protein kinase.

FAM156A mutations have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, several studies have identified potential drug targets and biomarkers for FAC. For example, some studies have shown that inhibition of the Ca2+-dependent protein kinase (Ca2+-dependent protein kinase) using small molecules can effectively reduce the severity of FAC symptoms in animal models.

Potential Drug Targets and Biomarkers for FAC

Several potential drug targets and biomarkers for FAC have been identified, including the Ca2+-dependent protein kinase (Ca2+-dependent protein kinase), CaM-PK, and the neurotransmitter systems, such as dopamine and opioids.

1. Ca2+-dependent protein kinase (Ca2+-dependent protein kinase)

Ca2+-dependent protein kinase (Ca2+-dependent protein kinase) is a protein that plays a crucial role in the regulation of intracellular signaling pathways, including the regulation of calcium homeostasis. Several studies have shown that inhibition of the Ca2+-dependent protein Kinase (Ca2+-dependent protein kinase) using small molecules can effectively reduce the severity of FAC symptoms in animal models. Additionally, some studies have shown that targeting the Ca2+-dependent protein kinase (Ca2+-dependent protein kinase) using small molecules can also inhibit the growth of cancer cells.

2.CaM-PK

CaM-PK is a protein that modulates the activity of Ca2+-dependent protein kinase (Ca2+-dependent protein kinase), which is involved in the regulation of intracellular signaling pathways, including the regulation of calcium homeostasis. Several studies have shown that targeting CaM-PK using small molecules can also inhibit the growth of cancer cells.

3. Neurotransmitter systems, such as dopamine and opioids

Neurotransmitter systems, such as dopamine and opioids, have also been identified as potential drug targets for FAC. Studies have shown that modulation

Protein Name: Family With Sequence Similarity 156 Member A

The "FAM156A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM156A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets